Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Biogen Reassessing Gene Therapy From Nightstar Deal After Phase II/III Miss

BIIB112, the gene therapy candidate Biogen picked up in $877m acquisition of Nightstar, missed its primary endpoint in X-linked retinitis pigmentosa. Phase III data for BIIB111, also from Nightstar, are expected soon.

Clinical Trials Gene Therapy Business Strategies

Curis And Autolus Rise On EHA Abstract Data

Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.

Commercial Companies Blood & Coagulation Disorders

More Competition Coming To Cushing's Market

Having been given a PDUFA target date of 1 January, 2022, Strongbridge is already preparing for a happy new year challenging Recordati's Isturisa for market share in the Cushing's syndrome space

Rare Diseases Strategy FDA
 

 

Click to read Six Themes That Will Shape Biopharma In Transformational 2021

Key Predictions From Industry Leaders

 

 

 


Recent Tweets from Scrip


 

Infographics

Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge

From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.

The 2021 Worldwide Pharma And Biotech R&D Scene

INFOGRAPHIC: A snapshot of the industry in key performance indicators surrounding R&D taken in early 2021.

Pandemic Perspectives: China Vaccine Diplomacy - A World On Shots

Over 50 countries around the world are now receiving COVID-19 vaccine deliveries from China, totaling 3.3 million doses and counting so far. This Scrip infographic shows their locations, quantity of supplies and the developers involved.

Commercial Explore this Topic

Set Alert for Commercial

Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities

A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.

Commercial Sales & Earnings

Heron Overcomes Two CRLs To Win Zynrelef Approval In Post-Op Pain

The combination of bupivacaine and meloxicam will be priced at a discount to Exparel, with Heron predicting rapid uptake. Label limited to three surgery types, but analysts expect off-label use.

Approvals Pricing Strategies

CDK4/6 Market: Is A Shakeup Underway?

Pfizer's Ibrance still dominates the category but sales slowed in the first quarter, while Novartis’s Kisqali and Lilly's Verzenio both grew double digits.

Cancer Pricing Strategies

Lundbeck's Migraine Therapy Vyepti: Overcoming The COVID-19 Effect

Denmark’s Lundbeck is aiming to build up use of its latest neurological, the long-acting migraine preventative, Vyepti, now that US healthcare is emerging from COVID-19-related restrictions, but is facing headwinds from loss of exclusivity on Northera.

Sales & Earnings Neurology

Rising US Sales, EU Milestone Boost SK Bio's Q1

After strong first-quarter results, SK Biopharmaceuticals expects sales growth to accelerate as the US marketing environment improves and as EU sales of epilepsy drug cenobamate begin.

Neurology South Korea

Perceptive And Xontogeny’s Second VC Fund Brings In $515m

The strategy for both funds is to back companies with a preclinical drug candidate that can be advanced through clinical proof-of-concept with a mid-sized series A round. 

Financing StartUps and SMEs
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?

IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.

Policy & Regulation Coronavirus COVID-19

Quick Listen: The Story Behind The Pharmaprojects’ Pharma R&D Annual Review 2021

In this one-off podcast, hear in the inside story of how the Pharmaprojects’ Pharma R&D Annual Review 2021 is put together, its history and the trends it has revealed in R&D over the years.

Research & Development Companies

Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge

From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.

India Coronavirus COVID-19
See All

Research & Development Explore this Topic

Set Alert for Research & Development

Pipeline Watch: Phase III Readouts In Cervical Cancer, COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

How A Small Chinese Biotech Is Taking On mRNA Vaccine Giants

Originated by a Suzhou-based biotech founded two years ago and now being jointly developed with WalVax, China’s first homegrown mRNA COVID-19 vaccine is now entering the final stages of development.

China Coronavirus COVID-19

Merck & Co.’s Keytruda Gets Fighting Chance In TNBC

The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.

ImmunoOncology Biologics
See All
UsernamePublicRestriction

Register